Zakrzewski Joseph S 4

What Happened Joseph S. Zakrzewski, a director of AN2 Therapeutics, was granted derivative securities covering 20,400 shares on Feb 20, 2026. The filing reports an acquisition price of $0.00 (derivative award), with a stated vesting condition — the shares will vest on February 20, 2027 subject to continuous service. This is a company grant/award (not an open‑market buy or sale) and does not reflect an immediate cash transaction or sale.

Key Details

• Transaction date: 2026-02-20; Form 4 filed: 2026-02-23 (filed within the required reporting window).
• Transaction type: Award/Grant of derivative securities (code A) — 20,400 shares reported at $0.00.
• Vesting: The option/award shares vest on 2027-02-20, contingent on continued service (per filing footnote).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax withholding, or cashless exercise noted.

Context This was a compensation award (derivative security) that will only vest after one year of continued service; it is not an immediate purchase of common stock nor an insider sale. Such awards are routine for directors and are intended as long‑term incentive compensation rather than a direct signal to trade.